Patient Profile

REPATHA®
APPROVED TO
REDUCE
CARDIOVASCULAR
RISK1

David: Age 62, retired teacher, married, father and grandfather*

  • First MI: 18 months ago
  • Progressive atherosclerosis
  • Subsequent MI: 3 months ago
  • Type 2 diabetes mellitus

 
  • David is assessed as “very high risk”
  • His Cardiologist decides to start Repatha® as David meets the following criteria:
 

Established atherosclerotic CV disease (MI, stroke, or peripheral arterial disease)
Optimised dietary and pharmacological lipid-lowering therapy (generally >12 months; atorvastatin 40 mg,
ezetimibe 10 mg)
Primary heterozygous familial hypercholesterolaemia or non-familial hypercholesterolaemia or mixed dyslipidaemia
LDL-C target not reached (on-treatment) LDL-C: 108 mg/dl (2.8 mmol/l)
 

In patients with a recent MI like David,
Repatha® substantially reduces the risk of further CV events*2

Key secondary endpoint (composite of CV death, MI, or stroke) in patients with MI <12 months (n=5711) ago2

Image

*The subject depicted is not a real patient.
p-values are nominal. Repatha® reduced the risk of the key secondary endpoint by 15% (p=0.009) in patients with a remote MI (>12 months). The p-value for interaction between recent and remote MI groups was not significant (p-int=0.24).
In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
§25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CI = Confidence interval; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; HR = Hazard ratio; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.
  1. Repatha® (evolocumab) Summary of Product Characteristics. Last revised: April 2020.
  2. Gencer B, et al. JAMA Cardiol. 2020; Online first. doi:10.1001/jamacardio.2020.0882.